xpanmedical.com
Innovation Type:
Medical Technologies
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose, Falcons' Fortunes, Prospects
Xpan's Universal Trocar System is a minimally invasive surgical innovation - a first of its kind, radially expanding trocar that can be tailored by surgeons during laparoscopic procedures to accommodate various sized instruments.

Related news

FACIT announces follow-on investments in Xpan Inc. and Nanology Labs through Compass Rose Fund

January 28, 2020 – Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund. Read More

FACIT generates $1.5 billion in follow-on investment

FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada. Read More

Entrepreneurs from Ontario’s Nanology Labs and Xpan Inc. receive FACIT investment for early-stage cancer innovations

April 8, 2019 – FACIT is pleased to announce recent successes in its mission to help bridge the capital gap often experienced by early-stage entrepreneurs. Read More

FACIT’s Prospects Oncology Fund invests in Ontario-developed medical device and novel therapeutic platform technologies

September 26, 2019 – FACIT announces investments in Xpan Inc. and innovations from OICR and the University of Toronto... Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.